HIV chemotherapy

Nature

Volumn 410, Issue 6831, 2001, Pages 995-1001

  Richman, D D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; HEALTH CARE; TOXICITY;

DRUG-RESISTANT VIRUS;

VIRUSES;

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DEVELOPING COUNTRY; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; HEALTH CARE UTILIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; MORTALITY; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

AIDS VACCINES; ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPING COUNTRIES; DRUG DESIGN; DRUG RESISTANCE, MICROBIAL; HIV; HIV INFECTIONS; HUMANS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0035912249     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/35073673     Document Type: Review

References (108)

1. Viral dynamics of HIV: Implications for drug development and therapeutic strategies
2. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR
3. Viral dynamics in human immunodeficiency virus type 1 infection
4. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
5. Polygenic and multifactorial disease gene association in man: Lessons from AIDS
6. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS
7. HIV-1 dynamics in vivo: Virion clearance rate, infected cell lifetime, and viral generation time
8. Quantitative image analysis of HIV-1 infection in lymphoid tissue
9. + T cell demographics and dynamics in lymphatic tissues
10. + lymphocytes as prognostic markers of HIV-1 infection
11. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA panel
12. + T cell depletion and viral replication in SIV infection
13. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs
14. Predominance of distinct viral genotypes in brain and lymph node compartments of HIV-1-infected individuals
15. HIV-1 V3 domain variation in brain and spleen of children with AIDS: Tissue-specific evolution within host-determined quasispecies
16. In vivo compartmentalization of HIV: Evidence from the examination of pol sequences from autopsy tissues
17. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: Evidence for viral compartmentalization and selection during sexual transmission
18. Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood
19. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
20. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
21. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
22. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
23. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
24. Decay characteristics of HIV-1-infected compartments during combination therapy
25. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection
26. + T cells
27. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
28. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy
29. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
30. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy
31. Time of initiation of antiretroviral therapy: Impact on HIV-1 viraemia
32. Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy
33. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
34. + T cell homeostasis and function in advanced HIV disease
35. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
36. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS clinical trials group protocol 315
37. Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection
38. + lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues
39. High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection
40. Changes in thymic function with age and during the treatment of HIV infection
41. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
42. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
43. Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects
44. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy
45. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy
46. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease
47. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection
48. Impact of protease inhibitors on AIDS-defining events and hospitalization in 10 French AIDS reference centres
49. Centers for disease control and prevention
50. Changing patterns of mortality across Europe in patients infected with HIV-1
51. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
52. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor
53. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1
54. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
55. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
56. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study
57. The relationship between ritonavir plasma levels and side-effects: Implications for therapeutic drug monitoring
58. HIV-protease inhibitors
59. Antiretroviral drugs and the central nervous system
60. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
61. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
62. Fat distribution and metabolic changes in patients with HIV infection
63. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
64. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase
65. Transmission and prevalence of HIV resistance among treatment-naive subjects
66. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use
67. Antiretroviral drug resistance testing in adults with HIV infection
68. Antiretroviral drug resistance testing in adult HIV-1 infection
69. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
70. The accuracy and reproducibility of high throughput genotypic and phenotypic HIV-1 resistance testing under EN45001 and CLIA accreditation labels
71. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
72. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: Week 48 follow-up
73. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
74. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
75. Identification of clinically relevant phenotypic and genotypic breakpoints for ABT-378/r in multiple PI-experience, NNRTI-naive patients
76. R165335-TMC125, a novel non nucleoside reverse transcriptase inhibitor (NNRTI) with nanomolar activity against NNRTI resistant HIV strains
77. Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS
78. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells
79. New targets for inhibitors of HIV-1 replication
80. Core structure of gp41 from the HIV envelope glycoprotein
81. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
82. Protein design of an HIV-1 entry inhibitor
83. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 coreceptor
84. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
85. The care of HIV-infected adults in the United States
86. Estimating the national cost of treating people with HIV disease: Patient, payer, and provider data
87. Costs of HIV medical care in the era of highly active antiretroviral therapy
88. Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration hospital
89. Cost effectiveness of combination HIV therapy: 3 years later
90. The affordability of antiretroviral therapy in developing countries: What policymakers need to know
91. Variations in the care of HIV-infected adults in the United States
92. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa
93. Prevention of mother-to-child HIV transmission in resource-poor countries: Translating research into policy and practice
94. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease
95. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection
96. + T cell responses associated with control of viremia
97. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
98. Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasma load of viral RNA
99. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
100. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques
101. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
102. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques
103. Immune control of HIV-1 after early treatment of acute infection
104. Control of SIV rebound through structured treatment interruptions during early infection
105. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
106. 3-Year suppression of HIV viremia with indinavir, zidovudine and lamivudine